In Situ Tumor Surface Modification with Antibody Fragments for Antigen-Independent Versatile Cancer Immunotherapy
ACS Nano · 2025
DOI: 10.1021/acsnano.5c08128 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, 2025. Verfasst von Seonwoo Kang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, POSTECH-CATHOLIC Biomedical Engineering Institute, Pohang University of Science and Technology (POSTECH), Pohang 37673, Repu…. Hauptthemen laut MEDLINE: Immunotherapy, Immunoglobulin Fc Fragments, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: National Research Foundation of Korea, Korea Evaluation Institute of Industrial Technology.
Abstract (Originalsprache)
Natural killer (NK) cells exert potent cytotoxic effects by releasing perforin, granzyme B, and immune-boosting cytokines upon recognition of antibody-coated targets. However, the heterogeneous expression of tumor antigens poses a major limitation to NK-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). To overcome this challenge, we developed a Universal Antibody (Univody), a recombinant fusion protein that enables an antigen-independent presentation of Fc fragments on the surface of cancer cells. Specifically, the Fc region of human IgG1 was fused with a transmembrane domain and delivered in the form of plasmid DNA, ensuring stable membrane localization and interaction with NK cell receptors. For efficient and selective delivery, we employed a phenylboronic acid (PBA)-modified lipopolyplex (LPP-PBA), which significantly enhanced cellular uptake and transfection efficiency while reducing cytotoxicity. The plasmid DNA encoding Univody (pUnivody) effectively decorated a variety of heterogeneous tumor types with Fc fragments, leading to NK cell activation and enhanced immune responses in the tumor microenvironment. In vivo, pUnivody@LPP-PBA treatment resulted in marked tumor inhibition in both triple-negative breast cancer and melanoma models. This antigen-independent platform broadens the scope of antibody therapy and immunotherapy, offering a versatile approach to treating multiple types of cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, POSTECH-CATHOLIC Biomedical Engineering Institute, Pohang University of Science and Technology (POSTECH), Pohang 37673, Republic of Korea.
- Department of Molecular and Medical Pharmacology, California NanoSystems Institute (CNSI), Crump Institute for Molecular Imaging, University of California (UCLA) Los Angeles, 570 Westwood Plaza, Los Angeles, California…
- OmniaMed Co, Ltd., Pohang 37673, Republic of Korea.
ORCID-Profile: Junseok Lee, Won Jong Kim
Förderung
- National Research Foundation of Korea
- Korea Evaluation Institute of Industrial Technology
Zitieren
APA
Kang, S., Kang, Y., Lee, Y., Park, J., Lee, J., & Kim, W. J. (2025). In Situ Tumor Surface Modification with Antibody Fragments for Antigen-Independent Versatile Cancer Immunotherapy. ACS Nano. https://doi.org/10.1021/acsnano.5c08128
Vancouver
Kang S, Kang Y, Lee Y, Park J, Lee J, Kim WJ. In Situ Tumor Surface Modification with Antibody Fragments for Antigen-Independent Versatile Cancer Immunotherapy. ACS Nano. 2025. doi:10.1021/acsnano.5c08128
BibTeX
@article{Kang2025,
author = {Kang, Seonwoo and Kang, Yeoul and Lee, Yelim and Park, Jaehyun and Lee, Junseok and Kim, Won Jong},
title = {In Situ Tumor Surface Modification with Antibody Fragments for Antigen-Independent Versatile Cancer Immunotherapy},
journal = {ACS Nano},
year = {2025},
doi = {10.1021/acsnano.5c08128}
}
EUVIMED